Vitamin K specialist Natto Pharma (Lysaker, Norway) announced on Wednesday that the company has successfully defended two EU patents for vitamin K1 and K2 in heart health. The first patent claims vitamin K's use for decalcification of blood vessels and the second claims its use in preventing age-related stiffening of arteries, the company reported.
Vitamin K specialist Natto Pharma (Lysaker, Norway) announced on Wednesday that the company has successfully defended two EU patents for vitamin K1 and K2 in heart health.
The first patent claims vitamin K's use for decalcification of blood vessels and the second claims its use in preventing age-related stiffening of arteries, the company reported.
The news further bolsters Natto Pharma's presence in a vitamin K market that is receiving new attention thanks to increasing research on the nutrient's cardiovascular and bone health benefits. The company manufactures MenaQ7, a source of K2 that has been the subject of dozens of published studies on K2.
"The EPO approval and confirmation of these two patents represents a milestone for NattoPharma," said Natto Pharma CEO Peter Carlsson. "This will significantly strengthen NattoPharma's intellectual property rights and contribute to NattoPharma's competitive advantage and the ability to support our customers and partners in the marketing of MenaQ7 within the food supplement market as well as the functional food market."
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.